Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

BACKGROUND: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. METHODS: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Blum, Vinicius Fontanesi, Cimerman, Sérgio, Hunter, James R, Tierno, Paulo, Lacerda, Acioly, Soeiro, Alexandre, Cardoso, Florentino, Bellei, Nancy Cristina, Maricato, Juliana, Mantovani, Nathalia, Vassao, Marcella, Dias, Danilo, Galinskas, Juliana, Janini, Luis Mário Ramos, Santos-Oliveira, Joanna Reis, Da-Cruz, Alda Maria, Diaz, Ricardo Sobhie
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8235996/
https://ncbi.nlm.nih.gov/pubmed/34222847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100981
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars